-
Jan 17, 2025 | 
streetinsider.com | Restated Certificate
1. JBHT2. INFY3. SPY4. NVDA5. INFO:IN6. STT7. MS8. SLB9. LTIM:IN10.
-
Dec 9, 2024 | 
mx.advfn.com | Restated Certificate
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-283533 PROSPECTUS 37,499,981 Shares of Common Stock This prospectusrelates to the proposed resale from time to time by the selling stockholders identified in this prospectus of up to 37,499,981 shares of our common stock, par value $0.0001 per share.
-
Dec 5, 2024 | 
mx.advfn.com | Restated Certificate |Restated Bylaws
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-279196 PROSPECTUS SUPPLEMENT (to Prospectus dated May 8, 2024) 5,317,460 Shares of Common Stock Pre-Funded Warrants to Purchase 238,095 Shares of Common Stock We are offering 5,317,460 shares of our common stock at a purchase price of $63.00 per share, and in lieu of offering shares of our commonstock to certain investors that so choose, pre-funded warrants to purchase 238,095 shares of our common stock.
-
Nov 29, 2024 | 
mx.advfn.com | Restated Certificate |Restated Bylaws
As filed with the Securities and Exchange Commission on November 29, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THESECURITIES ACT OF 1933 Lyell Immunopharma, Inc.
-
Nov 27, 2024 | 
mx.advfn.com | Restated Certificate |Restated Bylaws
Filed Pursuant to Rule 424(b)(5) Registration Statement No.333-280962 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 31, 2024) Canoo Inc. 7,185,125 Shares Common Stock We are issuing 7,185,125 shares of our common stock, par value $0.0001 per share (the “Common Stock”) in payment to certain vendors for services rendered or other payment obligations over the next several fiscal quarters under contractual arrangements between us and these vendors.
-
Nov 27, 2024 | 
mx.advfn.com | Restated Certificate |Restated Bylaws
Table of Contents Filed Pursuant to Rule 424(b)(3)Registration No. 333-283349 PROSPECTUSSUPPLEMENT Up to $113,792,846.40 Shares of Common Stock We previouslyentered into an Open Market Sale AgreementSM, or sales agreement, dated October 4, 2021, with Jefferies LLC, or Jefferies, relating to shares of our common stock offered by this prospectussupplement.
-
Nov 20, 2024 | 
streetinsider.com | Restated Certificate |Restated Bylaws
ArticleRelated Articles (1)Stock Quotes (1)1. WMT2. LOW3. AZEK4. BRBR5. DTM6. QCOM7. CAN8. VVV9. QSI10. TGT Tweet Share E-mail0 sharesTable of Contents As filed with the Securities and Exchange Commission onNovember 20, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THESECURITIES ACT OF 1933 PMV Pharmaceuticals, Inc.
-
Nov 20, 2024 | 
mx.advfn.com | Restated Certificate |Restated Bylaws
Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-280148 PROSPECTUS SUPPLEMENT (To Prospectus dated June 21, 2024) Up to $35,000,000 Common Stock We entered into a sales agreement dated November 19, 2024 (the Sales Agreement) with Needham & Company, LLC and H.C. Wainwright & Co., LLC (each, a Sales Agent and together, the Sales Agents), relating to the issuance and sale of shares of our common stock, $0.001 par value per share, offered by this prospectus supplement...
-
Nov 20, 2024 | 
mx.advfn.com | Anti-Takeover Effects |Certain Provisions |Restated Certificate |Restated Bylaws
Filed Pursuant to Rule 424(b)(5)Registration Statement No. 333-260316PROSPECTUS SUPPLEMENT(To Prospectus dated October 26, 2021)PROFESSIONAL DIVERSITY NETWORK, INC.
-
Nov 15, 2024 | 
mx.advfn.com | Restated Certificate |Restated Bylaw Provisions
As Filed Pursuant to Rule 424(b)(5) Registration No. 333-283001PROSPECTUS SUPPLEMENT(To Prospectus Dated November 15, 2024)AnaptysBio, Inc. $100,000,000Common StockWe have entered into a sales agreement, or the sales agreement, with TD Securities (USA) LLC, or TD Cowen, relating to the sale of shares of our common stock, $0.001 par value per share, offered by this prospectus supplement and the accompanying base prospectus.
